Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
ACADEMIA
I/O Pioneers Win Nobel Prize in Medicine; Honjo Prods Japan Firms to Make More Academic Investment at Home
Immunotherapy trailblazers James Allison and Tasuku Honjo on October 1 jointly won the 2018 Nobel Prize in medicine for their revolutionizing discoveries on how the human immune system can be harnessed to fight cancer. The discoveries of Dr Allison, an…
To read the full story
Related Article
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Ono, Prof. Honjo Disagree About Validity of Patent Royalty Rate for Opdivo
January 6, 2021
- Ono Says Honjo’s 22.6 billion Yen Claim Groundless, No Agreement Reached on 40% Opdivo Fee Proposal
October 27, 2020
- Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
- Nobel Laureate Honjo Sues Ono over Opdivo Royalties, Demands 22.6 Billion Yen
June 22, 2020
- Ono President Confident of Validity of Company’s Argument on Opdivo Royalties
June 19, 2020
- Nobel Laureate Honjo Taking Ono to Court, Demands 22.6 Billion Yen
June 8, 2020
- Royalty Feud with Nobel Laureate Takes Center Stage at Ono Shareholder Meeting
June 21, 2019
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize
October 3, 2018
ACADEMIA
- Wegovy First Med to Meet Guidelines Criteria for Obesity Drug Development
March 30, 2023
- Obesity Med Wegovy Could Be “Ace in the Hole”, Should Avoid Fate of Oblean: KOL
March 30, 2023
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
- Japan’s Antimicrobial Use in 2022 Levels Off YOY, Down 31.5% from 2013
March 10, 2023
- Probe Panel Recognizes Professor’s COI over Glactiv Scandal, but Doubts Whether It Constitutes Bribery
February 24, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…